A. Musolino, M. Campone, P. Neven, N. Denduluri, C. Barrios, J. Cortés, K. Blackwell, H. Soliman, Z. Kahán, H. Bonnefoi, M. Squires, Yong Zhang, S. Deudon, M. Shi, F. André
{"title":"dovitinib联合氟维司汀治疗绝经后HR+、HER2−乳腺癌患者,这些患者在既往内分泌治疗期间或之后发生进展,该研究是一项随机、安慰剂对照研究","authors":"A. Musolino, M. Campone, P. Neven, N. Denduluri, C. Barrios, J. Cortés, K. Blackwell, H. Soliman, Z. Kahán, H. Bonnefoi, M. Squires, Yong Zhang, S. Deudon, M. Shi, F. André","doi":"10.1186/s13058-017-0807-8","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":9222,"journal":{"name":"Breast Cancer Research","volume":"25 1","pages":""},"PeriodicalIF":6.1000,"publicationDate":"2017-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"84","resultStr":"{\"title\":\"Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2− breast cancer that had progressed during or after prior endocrine therapy\",\"authors\":\"A. Musolino, M. Campone, P. Neven, N. Denduluri, C. Barrios, J. Cortés, K. Blackwell, H. Soliman, Z. Kahán, H. Bonnefoi, M. Squires, Yong Zhang, S. Deudon, M. Shi, F. André\",\"doi\":\"10.1186/s13058-017-0807-8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":9222,\"journal\":{\"name\":\"Breast Cancer Research\",\"volume\":\"25 1\",\"pages\":\"\"},\"PeriodicalIF\":6.1000,\"publicationDate\":\"2017-02-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"84\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Breast Cancer Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s13058-017-0807-8\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Cancer Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13058-017-0807-8","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2− breast cancer that had progressed during or after prior endocrine therapy
期刊介绍:
Breast Cancer Research is an international, peer-reviewed online journal, publishing original research, reviews, editorials and reports. Open access research articles of exceptional interest are published in all areas of biology and medicine relevant to breast cancer, including normal mammary gland biology, with special emphasis on the genetic, biochemical, and cellular basis of breast cancer. In addition to basic research, the journal publishes preclinical, translational and clinical studies with a biological basis, including Phase I and Phase II trials.